Acronyms appearing in AVXL postings (incomplete — feel free to amend):
__________________________
AD — Alzheimer’s Disease
ADCS-ADL — Alzheimer's Disease Cooperative Study - Activities of Daily Living; measures the ability to independently perform daily activities such as eating, bathing, and using the telephone; [unable to discover the meaning of scoring data; presumably higher is favorable]
BIIB — Biogen, Inc.; a major pharmaceutical company, apparently in discussion with Anavex concerning Anavex 2-73 development, testing, and perhaps marketing
BP – Big Pharma, or Big Pharmaceuticals; any of the established, giant drug development and drug sales companies.
CNS — Central Nervous System; the brain and spinal cord; the bodily location of central nervous system disorders, such as Alzheimer’s disease and Parkinson’s disease
CTAD — Clinical Trials on Alzheimer's Disease; a current or recent meeting of neuroscience researchers where neuroscience reports are posted and presented
EEG — Electroencephalogram; observes electrical activity in the brain; abnormal activity associated with neurological diseases and conditions
ERG — Electroretinography — measures electrical responses of cells in the retina; can reveal neurological problems
HAM-D — Hamilton Rating Scale for Depression; rates the severity of depression
MMSE — Mini-Mental Status Examination; 30-point questionnaire in clinical and research settings to measure cognitive impairment; higher scores indicate higher cognition (thinking) skills.
MTD — Maximum Tolerated Dose; the highest dose of a radiological or pharmacological treatment that will produce the desired effect without unacceptable toxicity
PD — Parkinson’s Disease
Phase 1 – Initial clinical study of a new drug; to determine dose range toleration and pharmacokinetics
Phase 2a: — Pilot clinical trial to evaluate efficacy (and safety) in selected populations
of patients with the disease or condition to be treated, diagnosed, or prevented.
Objectives may focus on dose-response, type of patient, frequency of dosing, or
numerous other characteristics of safety and efficacy.
PK — “pharmacokinetics;” the progression and fate of an administered chemical or drug in the body
